| Id: | acc5101 |
| Group: | 1sens |
| Protein: | JNK1 |
| Gene Symbol: | Mapk8 |
| Protein Id: | P49185 |
| Protein Name: | MK08_RAT |
| PTM: | phosphorylation |
| Site: | Tyr185 |
| Site Sequence: | AGTSFMMTPYVVTRYYRAPEV |
| Disease Category: | Nervous system diseases |
| Disease: | Spinal Cord Injury |
| Disease Subtype: | |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | SP600125 |
| Drug Info: | "SP600125 is a potent, cell-permeable, and selective c-Jun N-terminal kinase (JNK) inhibitor with an IC?? value in the low nanomolar range. It has been widely used in research to study the role of JNK signaling pathways in various cellular processes and diseases. " |
| Effect: | modulate |
| Effect Info: | "SCI leads to a significant increase in the phosphorylation level of JNK, promoting local cell apoptosis and nerve injury. The use of SP600125 can inhibit JNK phosphorylation (without affecting the phosphorylation of p38 and ERK1/2), reduce tissue damage, and improve motor function." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 27080425 |
| Sentence Index: | 27080425_5 |
| Sentence: | "Intrathecal administration of a specific inhibitor of JNK phosphorylation, SP600125, given at 1 and 4h after SCI, reduced the p-JNK expression, the number of spinal apoptotic cells and many of the histological signs of spinal injury." |
Sequence & Structure:
MSRSKRDNNFYSVEIADSTFTVLKRYQNLKPIGSGAQGIVCAAYDAILERNVAIKKLSRPFQNQTHAKRAYRELVLMKCVNHKNIIGLLNVFTPQKSLEEFQDVYIVMELMDANLCQVIQMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSFMMTPYVVTRYYRAPEVILGMGYKENVDLWSVGCIMGEMVCLKILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRTYVENRPKYAGYSFEKLFPDVLFPADSEHNKLKASQARDLLSKMLVIDASKRISVDEALQHPYINVWYDPSEAEAPPPKIPDKQLDEREHTIEEWKELIYKEVMDLEERTKNGVIRGQPSPLGAAVINGSQHPVSSPSVNDMSSMSTDPTLASD
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| Y | 185 | D | Alzheimer's disease | Phosphorylation | 23474850 |
| Y | 185 | D | Short-term oestrogen deprivation | Phosphorylation | 23474850 |
| Y | 185 | U | Alzheimer's disease | Phosphorylation | 23474850 |
| Y | 185 | U | Short-term oestrogen deprivation | Phosphorylation | 23474850 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
